Drug Profile

KCNQ2/3 channel modulator - Protheragen

Latest Information Update: 28 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Protheragen
Class Antiepileptic drugs
Mechanism of Action KCNQ2 potassium channel modulators; KCNQ3 potassium channel modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Jul 2024 No recent reports of development identified for preclinical development in Epilepsy in USA
22 Jun 2020 KCNQ2/3 channel modulator is available for licensing as of 22 Jun 2020. https://www.protheragen.com/pipeline.html
22 Jun 2020 Preclinical trials in Epilepsy in USA (unspecified route), prior to June 2020 (Protheragen pipeline, June 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com